NCT05627752 2024-02-28
Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage
Zhongnan Hospital
Phase 2/3 Unknown
Clinical Trials
11 trialsNCT04419402 2024-02-07
ENZA-p
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT02935205 2023-11-29
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
University of California, Davis
Phase 1/2 Unknown
NCT01949337 2023-09-28
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT04139772 2023-03-24
Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.
National Cancer Institute, Naples
Phase 3 Unknown
NCT04116775 2022-06-23
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
Portland VA Medical Center
Phase 2 Unknown
NCT05212857 2022-03-16
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Fudan University
Phase 2 Unknown
NCT03644303 2019-11-14
TRAP
Royal Marsden NHS Foundation Trust
Phase NA Unknown
NCT03196388 2018-01-18
ENZART
Fundación Canaria de Investigación Sanitaria
Phase 2 Unknown
NCT02254785 2017-12-06
Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
British Columbia Cancer Agency
Phase 2 Unknown
NCT03124615 2017-04-24
EFFECT
Macquarie University, Australia
Phase 2 Unknown